Robot model
Dexter
Distalmotion (founded 2012 in the Lausanne area of Switzerland as an EPFL spinout; private) makes Dexter, a hybrid laparoscopic surgical robot designed for cost-efficiency and operating-room integration that lets surgeons switch between robotic and manual laparoscopy within the same procedure. Dexter is a genuine master-controlled robotic manipulator that received its European CE mark in December 2020, with European market launch following in 2021, and then crossed the key US gating event with FDA De Novo marketing authorization in October 2024 for adult inguinal hernia repair, since expanded with two further US clearances covering cholecystectomy and gynecologic procedures including total benign hysterectomy. The company reports nearly 3,000 patients treated across Europe and the US, raised $150 million in November 2025 to accelerate US expansion, and positions Dexter for ambulatory surgical centers as a cost-efficiency play. The registry records it at commercial maturity, solidly past its gating events and in early US scale-up, with a teleoperated master-slave baseline and no shipped autonomy or AI-assist feature. One date-precision note: the CE mark is December 2020, while the 2021 figure sometimes cited refers to the European launch year. Exact installed-system and country counts are not verified for the private company, and the roughly 3,000-patients figure is company-sourced and plausible but not regulatory-audited.
Dexter is a surgical robot built by Distalmotion.
Machine-readable surfaces
- Markdown mirror: /models/distalmotion-dexter.md
- JSON-LD: embedded in this page’s head
- REST API: /v1/models/93cb82fd-9fa8-40f5-931c-2d36a8689fb9
- Data documentation: /data
- Form factor
- surgical
- Maturity stage
- commercial
- Lifecycle
- active
- Deployments
- 0
- ID
93cb82fd-9fa8-40f5-931c-2d36a8689fb9
Specs
- notes
- [object Object],[object Object],[object Object],[object Object]
- products
- Dexter: a hybrid laparoscopic surgical robot designed for cost-efficiency and OR integration, letting surgeons switch between robotic and manual laparoscopy in the same procedure. CE mark Dec 2020; FDA De Novo Oct 2024 (inguinal hernia repair); two further US indications (cholecystectomy; gynecology incl. total benign hysterectomy).
- formFactor
- surgical (hybrid laparoscopic teleoperated robot: switch between robotic and manual laparoscopy mid-procedure)
Supply chain
No verified supply relationships on file. Supply-chain coverage is being added across the registry; check back as the seed populates this model’s suppliers.
Suppliers appear here when verified with at least two strong sources (maker-official / IR / regulatory / standards-body / verified tier-2). Sources are append-only; corrections add new sources rather than rewrite history.
Sources (4)
Common questions
- What is Dexter?
- Distalmotion (founded 2012 in the Lausanne area of Switzerland as an EPFL spinout; private) makes Dexter, a hybrid laparoscopic surgical robot designed for cost-efficiency and operating-room integration that lets surgeons switch between robotic and manual laparoscopy within the same procedure. Dexter is a genuine master-controlled robotic manipulator that received its European CE mark in December 2020, with European market launch following in 2021, and then crossed the key US gating event with FDA De Novo marketing authorization in October 2024 for adult inguinal hernia repair, since expanded with two further US clearances covering cholecystectomy and gynecologic procedures including total benign hysterectomy. The company reports nearly 3,000 patients treated across Europe and the US, raised $150 million in November 2025 to accelerate US expansion, and positions Dexter for ambulatory surgical centers as a cost-efficiency play. The registry records it at commercial maturity, solidly past its gating events and in early US scale-up, with a teleoperated master-slave baseline and no shipped autonomy or AI-assist feature. One date-precision note: the CE mark is December 2020, while the 2021 figure sometimes cited refers to the European launch year. Exact installed-system and country counts are not verified for the private company, and the roughly 3,000-patients figure is company-sourced and plausible but not regulatory-audited.
- Who makes Dexter?
- Dexter is made by Distalmotion, based in Lausanne, Switzerland, founded in 2012.
- Where is Dexter deployed?
- No verified deployments of Dexter are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.
- What is Dexter's maturity stage?
- Dexter is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.